Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Another leap! Lizhu Group's MSCI ESG rating has been upgraded to AA.
Time Posted：2022-08-02 11:24
Recently, MSCI (Morgan Stanley Capital International), a leading international index company, announced its latest annual ESG (Environmental, Social and Governance) ratings. Thanks to its excellent ESG management and performance in 2021, in July 2022, Lizhu Group's MSCI ESG rating was upgraded two levels from BBB to AA. In particular, its performance on "Product Safety and Quality" and "Pollutant and Waste Emissions" is among the best in its global industry.
Time Posted：2022-07-29 15:51
On the evening of July 27, Joincare Pharmaceutical Group Industry Co., Ltd. (600380.SH) announced that its subsidiary, Lizhu Pharmaceutical Group Co., Ltd., received an approval notice from the National Medical Products Administration for its isosorbide mononitrate tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs.
Lizhu Group: The company's V-01 and V-01D-351 provide a better option for sequential strengthening
Time Posted：2022-07-21 17:12
Recently, an investor asked Lizhu Group on the interactive platform of the Shanghai Securities News: "In addition to V-01, does the company have any research and development related to the recently widely prevalent Omicron variant? What is the progress?" Lizhu Group responded that it has been closely monitoring the global COVID-19 pandemic trend and the prevalence of COVID-19 variants, and actively conducting research and development of variant vaccines. Relying on the mature recombinant protein vaccine R&D technology platform of Lizhu monoclonal antibody, the company has developed a variety of variant vaccines including Beta, Delta, and Omicron, as well as related bivalent vaccines, and has conducted relevant research on booster/sequential immunization in animals and investigator-initiated clinical trials.
The Chinese Academy of Sciences and Lizhu have made a new breakthrough in vaccine research.
Time Posted：2022-07-21 16:33
On July 18, research data on the recombinant novel coronavirus fusion protein vaccine V-01 and the bivalent vaccine V-01D-351 sequential booster immunization, jointly developed by Lizhu Group's subsidiary Lizhu Monoclonal Antibody and the Institute of Biophysics, Chinese Academy of Sciences, was published in the Journal of Clinical Medicine.
Time Posted：2022-07-15 17:47
In May 2022, Beijing InfiniChem Pharmaceutical Technology Co., Ltd. (InfiniChem) launched an upgraded version of its automatic molecular structure recognition tool, PharmaMind MolMiner V3.2 client. In addition, InfiniChem passed the ISO three-system certifications for Information Security Management System, Quality Management System, and Information Technology Service Management System, providing strong support for the company's R&D and strategic development. As InfiniChem's first independently developed and publicly released software product, the PharmaMind® client V3.2 version improves algorithm accuracy and usability compared to V3.0, and supports both Chinese and English language switching. It can be downloaded and used for free via the following link: Windows:
Time Posted：2022-07-06 20:46
June 30, 2022, was the cash dividend distribution date for Health Yuan (600380.SH) for the year 2021. According to the announcement, the company distributed a cash dividend of RMB 1.50 (including tax) per 10 shares, totaling RMB 278 million (including tax). In response, Health Yuan stated on the investor interaction platform that the company has implemented a positive profit distribution policy, striving to reward its investors while pursuing business performance and corporate value. Since February 2021, the company has also implemented two share buybacks. The first buyback amounted to RMB 700 million, and the second buyback amounted to RMB 300-600 million. Shares from both buybacks were used to reduce the company's registered capital. As of the end of May 2022, the company had repurchased nearly RMB 500 million. According to relevant regulations, share buybacks are considered equivalent to cash dividends.
Time Posted：2022-06-20 17:14
The development path of specialized and new "small giants" has been a prominent feature of the development of SMEs in China in recent years. They have become the vanguard supporting innovation and upgrading in manufacturing and high-quality economic development, and have laid a solid foundation for Shenzhen's innovative development. Shenzhen Haibin Pharmaceutical Co., Ltd., established in Yantian in 1989 and officially put into production in 1992, is now a listed pharmaceutical company focusing on the production of carbapenem products. It is a national high-tech enterprise and a Guangdong provincial specialized and new "small giant" enterprise with independent intellectual property rights integrating R&D and production.
Time Posted：2022-06-14 17:03
On June 10, a research paper on Lizhu's "recombinant novel coronavirus fusion protein vaccine" (hereinafter referred to as V-01) was published in the journal Emerging Microbes & Infections. The latest Phase III clinical trial showed that 14 days after receiving a booster dose of V-01, the neutralizing antibody titers in the V-01 vaccine group increased significantly in the primary immunization population who had been vaccinated with inactivated vaccines. The experiment confirmed that the heterologous booster immunization of V-01 vaccine is safe and effective, and can induce strong humoral immunity during the prevalence of Omicron and other variant viruses.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.